Biotech and drug manufacturing companies with the strength to weather further coronavirus storms Continue reading...
Medicare recipients will be able to get prescription plans that limit copays for insulin, a potential savings of hundreds of dollars, the White House announced Tuesday in a pivot to pocketbook issues that could influence November’s election.
On March 31, Fundsmith Equity Fund published an investor letter in which it has reported how the fund is faring in the coronavirus Covid-19 pandemic environment. The Fundsmith Equity Fund continues to operate and the fund has been able to provide liquidity where required. According to their management, "Fund’s performance has been as they would […]
The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M
Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
SNY vs. NVO: Which Stock Is the Better Value Option?
Drugmaker Eli Lilly & Co said on Tuesday it has capped the out-of-pocket cost for insulin to $35 per month to help diabetes patients across the United States, many of whom are facing financial difficulties due to the coronavirus outbreak. The new co-pay scheme covers most of Lilly's insulins, including widely-used Humalog injection, and can be availed by people with commercial insurance as well as those without insurance. "Enabling a $35-per-month insulin co-pay regardless of employment status will help many Americans in this difficult time," said CEOs Aaron Kowalski and Thom Scher of non-profit organization JDRF-Beyond Type 1 Alliance.
NVS vs. NVO: Which Stock Is the Better Value Option?
Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...
We recognize that people with chronic diseases, including diabetes, obesity and hemophilia, are at increased risk during this pandemic and Novo Nordisk is taking measures to support the communities we serve throughout the COVID-19 pandemic.
Image source: The Motley Fool. Novo Nordisk A/S (NYSE: NVO)Q1 2020 Earnings CallMay 6, 2020, 7:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorHello and welcome to the Q1 2020 Novo Nordisk AS Earnings Conference Call.
Tracking Q2 and Full-Year 2020 Earnings Estimates
Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.
A week ago, Novo Nordisk A/S (CPH:NOVO B) came out with a strong set of quarterly numbers that could potentially lead...
Several European countries have banned the export of insulin in recent weeks, a move industry officials said was based on a misguided fear that the COVID-19 pandemic would cause shortages of a drug vital to millions of diabetes patients. EU curbs on drug exports during the coronavirus emergency mostly cover medication used to treat COVID-19, including muscle relaxants, painkillers and hydroxychloroquine.
European shares opened little changed on Wednesday as a batch of mixed earnings reports and simmering U.S.-China tensions added to doubts about a swift economic recovery even as many countries eased lockdown measures. The pan-European STOXX 600 index was flat as losses in oil and gas sector, following a recent surge, offset gains in healthcare shares. The global mood also remained fragile as U.S. President Donald Trump again took aim at China, urging it to be transparent about the origins of the novel coronavirus outbreak.
The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy
People with diabetes using Novo Nordisk Inc. insulin who have lost health insurance coverage because of a change in job status due to the COVID-19 pandemic may now be eligible for enrollment in our Diabetes Patient Assistance Program (PAP) and receive insulin free of charge for 90 days.